At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 260 enrolled
Drug / intervention
gadopiclenol +1 moredrug
Likely dose
gadopiclenol 2mlfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Efficacy and Safety of Gadopiclenol for Central Nervous System (CNS) Magnetic Resonance Imaging (MRI)
In Brief
A Phase 3 clinical trial evaluating gadopiclenol and Gadobutrol 1Mmol/mL Solution for Injection Vial for CNS Lesion and Blood Brain Barrier Defect. Completed, enrolled 260 participants across 33 sites in 11 countries.
Detailed Summary
This trial aimed to evaluate the Efficacy and Safety of gadopiclenol for Central Nervous System (CNS) Magnetic Resonance Imaging (MRI)
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsCNS Lesion, Blood Brain Barrier Defect
CountriesBelgium, France, Germany, Hungary, Italy, Mexico, Poland, South Korea, Spain, Taiwan, United States
Collaborators--
Timeline
Phase 3CompletedFinished
2020202120222023202420252026
Enrollment StartJun 2019
First PostedJun 2019
Primary CompletionSep 2020
TodayJul 2026
First PostedJun 24, 2019
Enrollment StartJun 3, 2019
Primary CompletionSep 11, 2020
TodayJul 2, 2026
Enrollment to primary: 1.3 yearsPosted 7.0 years ago
Interventions
gadopiclenoldrug
single intravenous (IV) bolus injection at a rate of 2ml/second
Gadobutrol 1Mmol/mL Solution for Injection Vialdrug
single intravenous (IV) bolus injection at a rate of 2ml/second